Thyroid nodules affect nearly two-thirds of the world population. Fine-needle biopsy with cytologic evaluation remains the diagnostic test of choice to distinguish benign from malignant thyroid nodules yet fails to discriminate as benign or malignant in up to one-third of cases. This review discusses the limitation of current cytopathologic evaluation, the development of thyroid molecular testing, and the strengths and limitations of commercially available tests. Initial cytomolecular testing sought to identify specific gene mutations associated with thyroid cancer. Although the presence of a mutation was strongly associated with cancer, the likelihood of identifying a mutation was low; therefore, the test had low sensitivity. Subsequent tests developed have sought to improve the accuracy of cytomolecular testing for thyroid fine-needle aspirations, both to reassure patients and providers when malignancy may be absent and to confirm the malignancy when present. The development of cytomolecular testing for thyroid nodules has informed and improved current understanding of thyroid nodule formation and progression. When used appropriately and with clear understanding of the advantages and disadvantages, cytomolecular testing has the potential to improve patient care in the setting of indeterminate thyroid nodules by helping to guide both the need for and the extent of thyroid surgery. Cancer 2018;124:888-98. V C 2017 American Cancer Society.
INTRODUCTION
Thyroid nodules are a common clinical problem worldwide, with studies suggesting that nearly two-thirds of the population harbor thyroid nodules when evaluated by ultrasound. 1 Although fine-needle aspiration (FNA) remains the diagnostic test of choice to distinguish benign from malignant thyroid nodules, cytology alone fails to classify thyroid nodules in 15% to 30% of cases. 2 Molecular testing for thyroid nodules has evolved rapidly over the past decade both to help improve the diagnostic accuracy of thyroid cytology for indeterminate cases and potentially to guide the extent of surgery as initial therapy for suspected thyroid malignancies. This report briefly reviews the development and current landscape of thyroid molecular testing in the management of thyroid nodules.
The objective, as thyroid molecular testing initially developed, was to reduce unnecessary diagnostic thyroid surgery for indeterminate thyroid nodules. The potential future direction is to help define prognosis and determine whether cytomolecular testing can reduce overtreatment of patients with low-risk malignancy while informing effective, tailored treatment for those with higher risk thyroid malignancies. This prognostic information has the potential to inform both surgical decisions and ongoing therapeutic decisions regarding the role of radioactive iodine therapy, and even the selection of targeted chemotherapy when necessary.
Although cytology is 1 of many clinical factors that inform decision making with regard to the management of thyroid nodules, additional risk factors to consider include: family history of thyroid malignancy, history of radiation exposure, nodule size, sonographic risk assessment, patient symptoms, and thyroid function. 3 Diagnostic test accuracy must also be considered, with evaluation of test sensitivity, specificity, and the underlying disease prevalence in the population. Bayes' theorem informs us that disease prevalence impacts the predictive value of a test (Fig. 1) . On the basis of given sensitivity and specificity, when the prevalence of disease increases, the positive predictive value (PPV) goes up, whereas negative predictive value (NPV) goes down, and vice versa. Diagnostic tests with a high sensitivity and high NPV are inherently good tests to "rule out" the presence of disease, depending on the disease prevalence within the population, suggesting that a negative test result has high accuracy (approximately 95%) to reassure patients and providers that cancer is not present in the thyroid nodule evaluated. Diagnostic tests with a high specificity and high PPV are good to "rule in" disease, suggesting that a positive test result has high accuracy to confirm that a nodule is indeed cancerous, similar to the risk of malignancy on histopathology observed on cytology results that are consistent with malignancy. However, the accuracy of the test must be interpreted with regard to the disease prevalence within the population evaluated. An ideal test would provide high sensitivity and high specificity, indicating high accuracy at distinguishing benign from malignant disease; however, as a general rule, increasing sensitivity tends to reduce specificity, and vice versa.
LIMITATIONS OF THYROID CYTOLOGIC AND HISTOPATHOLOGIC EVALUATION
Ultrasound and ultrasound-guided FNA has long been the primary method of evaluating thyroid nodules for malignancy. 4 Although it is highly accurate for the diagnosis of benign colloid nodules (the most common finding) and classic papillary thyroid carcinoma (PTC) (the most common thyroid malignancy), thyroid FNA is much less accurate for the diagnosis of follicular variant of PTC. Furthermore, the ability to distinguish between follicular (or Hurthle cell) adenomas and carcinomas requires histologic assessment for capsule or vascular invasion and thus cannot be diagnosed with cytology alone. In addition, several benign conditions pose cytologic challenges, such as hyperplastic adenomatoid nodules, and inflammatory conditions, such as lymphocytic (Hashimoto) or granulomatous thyroiditis. In many cases, thyroid FNA results are cytologically "indeterminate" and historically have required diagnostic thyroid surgery, primarily hemithyroidectomy/lobectomy, for a definitive diagnosis.
To address high variability in the reporting and classification of cytology findings, the Bethesda System for Reporting Thyroid Cytopathology was developed and published in 2009 (Fig. 2) . 5, 6 Although the Bethesda system has been widely adopted and clearly has improved the consistency of terminology and communication regarding the potential risk of malignancy of indeterminate cytologic findings, the rates of malignancy within the subcategories can vary widely by institution. Furthermore, significant interobserver and intraobserver variability exist in interpretation, with concordance rates of 65% to 75% for thyroid cytology and 90% for histopathology. 7 Cytomolecular testing of thyroid nodules has the potential to distinguish indeterminate as either benign or neoplastic (including both premalignant and malignant pathology) and thus to improve the quality of care and guide surgical decision making. However, the incorporation of molecular testing into the options for diagnosis in thyroid cancer may actually contribute to changes in cytopathology interpretation and changes in the rates of indeterminate nodules. 8 Even final histologic assessment of benign versus malignant disease is in transition, as indicated by the recent change in the nomenclature when discussing noninvasive, encapsulated follicular variant of PTC, which was recently changed to be considered nonmalignant and redefined as a noninvasive follicular tumor with papillary-like features (NIFTP). However, diagnostic lobectomy is still required for both pathologic diagnosis and clinical treatment of NIFTP. 9, 10 Similar to distinguishing between follicular adenoma and follicular carcinoma, histopathologic evaluation is necessary to exclude capsular or vascular invasion in the diagnosis of NIFTP.
THE DEVELOPMENT OF THYROID MOLECULAR TESTING
The initial development of immunohistochemical evaluation with Galectin-3 and other biomarkers demonstrated some potential to improve the diagnostic accuracy of thyroid cytology, but it lacked sufficient reproducibility and sensitivity to reliably exclude malignancy. 11 Subsequently, new investigations sought to identify specific gene mutations and gene rearrangements that were pathogenic in thyroid cancer. (Fig. 3) . The most common mutations identified in thyroid cancer improved the specificity of thyroid cytology, but it was still not a sensitive enough detection method to rule out cancer for cases in which no mutation was identified. 12 Approaching the question of benign versus malignant cytopathology from a different perspective, a gene expression classifier (GEC) was developed through an iterative process designed a priori to have a high sensitivity and high NPV, similar to the NPV of thyroid nodules diagnosed as benign on cytology. 13, 14 Designed specifically to help rule out malignancy, the Afirma GEC (Veracyte, South San Francisco, Calif) was developed to potentially decrease the rate of diagnostic surgeries in the case of indeterminate nodules.
In addition, as molecular testing was beginning to develop for clinical use to improve the diagnostic accuracy of thyroid FNA, The Cancer Genome Atlas (TCGA) project mapped the mutations attributed to both classical and follicular variants of PTC, significantly reducing the number of unknown specific mutations causing differentiated thyroid cancer. 15 Incorporating the new information obtained through TCGA, an updated gene panel using next-generation sequencing (NGS) was developed for clinical use (ThyroSeq NGS, v2.0 [and now v2.1]; CBLPath, Orlando, Fla). [16] [17] [18] This test was developed to improve the overall accuracy of molecular testing to identify both benign and malignant thyroid cytopathology by improving sensitivity and NPV with only a mild reduction in specificity and PPV.
Additional approaches to molecular testing for thyroid cytopathology include the development of micro-RNA (miRNA) testing. MiRNAs act as negative regulators of gene expression and may impact cellular processes that lead to carcinogenesis. Because miRNA expression may be dysregulated in thyroid cancer, this represents an additional approach to molecular test development with high sensitivity and high specificity. [19] [20] [21] The ultimate goal of all the described approaches to thyroid molecular testing is to improve the clinical management of patients with thyroid nodules. Reducing the number of unnecessary diagnostic thyroid surgeries has huge implications for overall patient quality of life and cost of health care. Therefore, as the number of patients with thyroid nodules continues to rise, the goal is to decrease potential morbidity for benign thyroid disease and to optimize initial treatment of thyroid cancer.
In the setting of a suspicious thyroid nodule with a clear gene mutation that identifies malignancy, thyroid cancer could be diagnosed before surgery and effectively decrease the number of patients who require a 2-part procedure for definitive primary treatment of thyroid cancer. The 7-gene specific mutation panel has been validated as an effective "rule-in" cytomolecular test for thyroid malignancy based on the high specificity and PPV (Table 1) , but it has not been considered an effective "rule-out" test because of low sensitivity ( Table 2) . The largest prospective, single-institution study included 247 Bethesda III thyroid nodules and 214 Bethesda IV thyroid Figure 3 . The mitogen-activated protein kinase (MAPK) pathway is the principal pathway leading to differentiated thyroid cancer. The phosphatidylinositol-4,5-bisphosphate 3-kinase-protein kinase B (PI3K-AKT) pathway is an important pathway leading to follicular thyroid cancer and undifferentiated thyroid cancer. a, b, and g indicate rearranged during transfection (RET) receptors a, b, and g, respectively; BRAF, v-Raf murine sarcoma viral oncogene homolog B1; ERK, extracellular signal-regulated kinase; GF, growth factor; GPT, glutamic-pyruvic transaminase; H-Ras, Harvey rat sarcoma viral oncogene homolog; K-Ras, Kirsten rat sarcoma viral oncogene homolog; MEK, mitogen activated protein extracellular signal-regulated kinase; mTOR, mammalian target of rapamycin; N, nucleus; N-Ras, neuroblastoma rat sarcoma viral oncogene homolog; Pax8/PPARc, paired box gene 8-peroxisome proliferator-activator receptor g; PTEN, phosphatase and tensin homolog; RAF, RAF proto-oncogene serine/threonine-protein kinase; RAS, a family of rat sarcoma (ras) small guanosine triphosphate hydrolases (GTPases); RET, rearranged during transfection; Ret/PTC, rearranged during transfection/papillary thyroid cancer 1; RTK, receptor tyrosine kinase.
nodules with both cytology and histologic follow-up. The investigators reported 63% sensitivity and 99% specificity for Bethesda III nodules and 57% sensitivity and 97% specificity for Bethesda IV nodules. A positive test result (the PPV) increased the cancer risk to 88% for Bethesda III nodules and 87% for Bethesda IV nodules, whereas the absence of a mutation or fusion was associated with a cancer risk of 6% (NPV, 94%) and 14% (NPV, 86%), respectively. 22 Although the early adoption of the 7-gene mutation panel to guide surgery was very positive, 22 with a significant decrease in the number of patients requiring a completion thyroidectomy, several changes in the overall approach to thyroid cancer treatment may limit this early promise. A more judicious approach to thyroid surgery has been recommended, as described in the 2015 American Thyroid Association guidelines, recognizing that a total thyroidectomy may not be the recommended initial surgery even for confirmed thyroid malignancies that are clinically considered low risk. 3 Early studies with the 7-gene mutation panel indicated that rat sarcoma (RAS) (a family of small guanosine triphosphate hydrolases) mutations were most common but were not highly specific for thyroid cancer, thereby limiting the PPV of the test. Recent studies have demonstrated that RAS mutations also can be identified in up to 48% of benign nodules; therefore, the type of RAS mutation and the degree of allelic frequency can be used to guide decision-making. 24 Similarly, many thyroid nodules with RAS and PAX8/ PPARc mutations are the histologically noninvasive encapsulated follicular variant of PTC, 10 now reclassified as NIFTP. 9 The definition of NIFTP was only recently published and reclassified to highlight the limited malignant potential of these precancerous lesions. However, treatment by lobectomy is still recommended. 9,10 The 2015 American Thyroid Association guidelines do not mandate a total thyroidectomy for differentiated thyroid cancer <4 cm with any of the mutations identified in the 7-gene mutation panel, further limiting its utility in either decreasing unnecessary surgery or guiding the extent of surgery for patients with indeterminate nodules. 13 Reducing staged completion thyroidectomy can only be achieved in the more limited circumstance for the patient with a highly specific mutation for cancer (BRAF and RET/PTC) coupled with a surgeon and patient favoring total thyroidectomy over lobectomy. 25 A "Rule-Out" Test: Afirma GEC With the development and adoption of the Bethesda classification system for cytopathology, 2 the estimated rates of malignancy in indeterminate nodules, ranging from 5% to 15% in Bethesda III nodules (atypia of undetermined significance/follicular lesion of undetermined significance) to 15% to 30% in Bethesda IV nodules (suspicious for follicular neoplasm/follicular neoplasm), remains too high to consider ongoing clinical surveillance (Tables 1 and 2 ). According to the guidelines proposed by the National Cancer Institute to define a good diagnostic test, a "good" test should rule out cancer in 95% of cases. Because a benign cytologic result on a thyroid FNA is thought to rule out malignancy in 97% of cases, a molecular test would ideally have similar accuracy to confirm benign disease. A GEC was developed with the objective of having high sensitivity and NPV, similar to those of thyroid nodules diagnosed as benign on cytology. 13, 14 The result of this process is a commercially available GEC (Veracyte), which uses an algorithm to evaluate the molecular expression of 167 genes to further classify cytologically indeterminate thyroid nodules into either benign or suspicious categories.
The initial prospective, blinded, multi-institutional validation study involving 577 indeterminate thyroid FNA samples, 265 of which were used for the validation analysis, reported 92% overall sensitivity and 52% specificity for indeterminate nodules classified as Bethesda III (atypia of undetermined significance/follicular lesion of undetermined significance), IV (follicular neoplasm/suspicious for follicular neoplasm), or V (suspicious for malignancy). The NPVs for a benign GEC result were 95%, 94%, and 85% for the 3 indeterminate Bethesda categories, respectively, with rates of malignancy among the 3 categories of 24%, 25%, and 62%, respectively.
14 Of the 7 false-negative results, 6 samples had insufficient follicular material for evaluation, but the seventh was an adequate sample in which the GEC failed to identify an invasive oncocytic carcinoma. Although the GEC test was not designed to provide high specificity or PPV, it is important to note that the PPV reported in the initial validation study for Bethesda III and IV nodules was 38%.
14 More recently, ongoing studies evaluating the accuracy of the Afirma GEC to effectively rule out malignancy have identified additional cases of malignancy with benign GEC results. 25 It is important for the patient and clinician to recognize that a suspicious classification by GEC is not a diagnosis of malignancy, nor is it equivalent to the Bethesda V suspicious for malignancy category. The notable exception is in medullary thyroid carcinoma, in which the PPV is 98% for the GEC. 26, 27 Designed to lower patient morbidity and the cost of care by decreasing unnecessary surgery for benign thyroid nodules, the majority of studies have demonstrated the utility of the Afirma GEC, whereas others have questioned the actual cost-benefit analysis of reflexively incorporating it into clinical care. 8, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Behind some of the various interpretations of the performance of the GEC are the inherent differences in agreement among thyroid cytopathologists. 7 However, another concern is the lack of a true "gold standard" in the subsequent validation studies, for which very few of the GEC benign cases have histologic correlation. This limitation prevents any further validation of the sensitivity and specificity of the GEC test and raises the concern of possible cases that have been misclassified as benign because of the limited length of follow-up in subsequent clinical validation studies.
Evaluation of the GEC test among unique cytopathologic classifications leads to additional questions about the utility of the GEC test in subsequently decreasing the number of patients sent for diagnostic surgery. Recent evaluation of which malignancies are detected by the GEC test reveal a high prevalence of the follicular-variant of PTC, many of which have been reclassified as NIFTP. 45 This suggests a growing role for limited surgery by hemithyroidectomy or lobectomy to treat low-risk malignancies or precancerous nodules with a "suspicious" GEC result. 46 In the setting of Hurthle cell lesions, recent data have indicated much higher rates of "suspicious" GEC results, ranging from 70% to 90%, but with much lower rates of malignancy, suggesting limited clinical utility in this specific population. [47] [48] [49] [50] Attempts to increase the PPV of a GEC "suspicious" result by adding the BRAF gene mutation test did not increase the PPV of the test result because of a low prevalence of classical PTC in the Bethesda III and IV categories.
Although it may be debatable whether the incorporation of cytomolecular testing into clinical care has improved clinical outcomes or influenced the overall cost of care, the addition of molecular testing in thyroid nodules has informed the overall discussion of thyroid nodules and the malignant potential of specific thyroid cytology results. The utility of the GEC for cytologically indeterminate nodules, as supported by the research and multiple validation studies published, should focus on the NPV of the test, which performs best when the estimated likelihood of malignancy based on clinical, sonographic, and cytologic evaluation is less than or equal to approximately 25% and patient preference is toward avoiding surgery if the GEC test is benign.
COMPREHENSIVE TESTS TO IMPROVE OVERALL ACCURACY

ThyroSeq NGS assay
The limitations of both the "rule-out" and "rule-in" approaches have been partially addressed with advances derived from TCGA that have been harnessed with NGS, a high-throughput sequencing analysis of large areas of the human genome (Tables 1 and 2) . 18 An NGS-based assay (ThyroSeq v2.0) is reported with 90% sensitivity, 93% specificity, an 83% PPV, and a 96% NPV, with prevalence of cancer at 25% for indeterminate thyroid nodules in a recent single-center study of 143 consecutive Bethesda IV nodules. 16 Subsequently evaluated for Bethesda III nodules, the commercially available version, ThyroSeq v2.1 (CBLPath), identifies 15 point mutations and 42 gene fusions with 90.9% sensitivity, 92.1% specificity, a 76.9% PPV, and a 97.2% NPV 17 . On the basis of both high sensitivity and high NPV, ThyroSeq v2.1 is promoted as a comprehensive test to both "rule in" and "rule out" thyroid malignancy.
A test with increasing sensitivity will inherently cause reduced specificity to some degree, as discussed above. The improvement in sensitivity and NPV of ThyroSeq v2.1 over the 7-gene mutation panel is achieved by testing for more pathogenic mutations. Although the NPV with ThyroSeq v2.1 is able to rule out malignancy with greater than 95% accuracy for both Bethesda III and Bethesda IV nodules while maintaining a relatively high PPV (approximately 75%), it is similar to the PPV for nodules deemed cytologically suspicious for malignancy but not as high as that for nodules cytologically diagnosed as malignant (>90%). In addition, ongoing research into the correlation of specific mutations with specific histopathologic correlations may help further guide surgical planning when a preoperative diagnosis of an indolent versus aggressive tumor mutation is identified. [51] [52] [53] ThyroSeq v2.1 has added potential benefit for expanding presurgical risk stratification by providing specific results for identified mutations. 29, 30 Prognosis and staging-based treatment decisions have been extensively studied for the BRAF mutation. Multivariate analysis in some but not all studies [54] [55] [56] [57] [58] [59] [60] have demonstrated that BRAF is an independent predictor of recurrence. However, BRAF mutation does not appear to improve prognosis or direct treatment beyond traditional TNM classifications, and the independent use of BRAF would incorrectly upstage the majority of indolent behaving, lower stage classical PTCs. Furthermore, it has been demonstrated that certain RAS mutations have a higher likelihood of distant metastasis and increased mortality compared with BRAF mutations, but RAS mutations can also be identified in benign follicular adenomas and in the noninvasive encapsulated follicular variant of PTCs (NIFTP), now reclassified as a premalignant tumor. 24 Two molecular markers that appear to confer an increased risk of tumor recurrence and tumor-related mortality are tumor protein 53 (TP53) and telomerase reverse transcriptase (TERT) mutations. TP53 mutations are late events in tumor clone progression and have been known to occur mostly in poorly differentiated and anaplastic thyroid cancers, often deriving from well differentiated PTCs. 40 TERT mutation is an independent predictor of disease-free survival. 61 The combination of a TERT mutation and a BRAF or Ras mutation within the same tumor is associated with a high risk of structural disease recurrence and mortality. 39, [60] [61] [62] [63] However, these are rare mutations and often clinically present with advanced and aggressive disease; thus, the current state of thyroid molecular testing does not add significantly to prognosis and treatment decisions beyond traditional pathologic and summary TNM staging. 51 Although the role of using molecular testing to guide treatment decisions beyond the primary management of thyroid nodules remains unknown, ongoing research is working to expand our understanding and ability to further risk stratify thyroid cancer and potentially guide early treatment decisions, including the extent of surgery.
ThyGenX/ThyraMIR
ThyGenX/ThyraMIR (Interpace Diagnostics, Parsippany, NJ) is also promoted as a comprehensive test with both high PPV and high NPV, based on very limited published data. This 2-part molecular test incorporates the original 7-gene mutation panel along with the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) mutation, labeled as ThyGenX. PIK3CA mutation is associated with follicular carcinoma and undifferentiated carcinoma. 21 If the ThyGenX panel has no mutation, then the ThyraMIR test is reflexively offered. ThyraMIR is a 10-miRNA GEC. This test was validated in a cross-sectional cohort analysis of 109 samples of thyroid FNA material from Bethesda III and IV nodules with paired histologic specimens, which were gathered across 12 clinical institutions with cytology and pathology specimens evaluated locally, without central adjudication of cytology or pathology results. In that small study, only samples with paired histopathology were included, and only 35 of the enrolled samples had malignant pathology. When evaluating the characteristics of this test for Bethesda III and IV nodules combined, the sensitivity of the ThyGenX/ThyraMIR test was 89%, with 85% specificity, a 68% PPV, and a 97% NPV for Bethesda III nodules (91% for Bethesda IV nodules), with an overall cancer prevalence rate of 32%. 21 Additional clinical validation of this test is warranted to determine how effectively and accurately the ThyGenX/ThyraMIR platform can help distinguish between benign and neoplastic thyroid nodules.
Rosetta GX Reveal
MiRNAs are an important class of noncoding RNAs implicated in gene expression regulation, and their expression profiles have been associated with the pathophysiology of cancer, including thyroid cancer. Rosetta GX Reveal (Rosetta Genomics Ltd, Rehovot, Israel) 20 is a miRNA-based assay for diagnosing indeterminate thyroid FNAs using stained FNA smears prepared for initial cytopathologic evaluation. The assay classifier measures 24 miRNAs. In this test, expression levels of a set of miRNA biomarkers are measured and used to classify thyroid nodules as benign or suspicious, and its analytical validity has been reported, supporting this novel approach to molecular testing using thyroid FNA smears prepared from routine cytology slides. 20 This approach to molecular testing may prove to be less invasive for patients by allowing the use of cytology slides for the acquisition of cellular material rather than requiring a repeat thyroid FNA or dedicated collection of sample material at the time of original the FNA.
A blinded, retrospective, multicenter validation of the novel Rosetta GX Reveal assay was recently published evaluating its performance on 189 FNA samples (Bethesda III-V nodules) with matched surgical specimens. 63 The study outlined 3 phases leading to the discovery of specific miRNAs for inclusion in the assay, the training of the assay classifier, and the final validation set, including 189 FNA samples. Overall performance characteristics revealed 85% sensitivity, 72% specificity, a 59% PPV, and a 91% NPV. Several post hoc analyses were included in the published results, separating the validation set into an "agreement" set, in which pathology was concordant among 3 pathologists. This improved the performance characteristics, suggesting that the assay performance may vary based on the accuracy of the histopathology results as well. Nine malignant samples were misclassified as benign, 5 of which were the encapsulated follicular variant of PTC, 2 were classic PTC, 1 was a nonencapsulated variant of PTC, and 1 was a follicular carcinoma with minimal capsular invasion.
The Rosetta GX Reveal assay adds a unique approach to molecular testing for thyroid FNA samples by using a cytology slide, thereby minimizing the impact to the patient at the time of FNA. This assay does not require a specialized sample-collection kit and thus may provide an option for molecular testing when needed rather than requiring specific sample collection at the time of the initial procedure. The validation data currently available highlight the challenges of using the miRNA platform for distinguishing between benign and neoplastic thyroid nodules but point to areas for further growth and development of this assay. Although additional validation will help further define the utility of this test specifically in Bethesda III versus Bethesda IV nodules, the recent publication adds to the growing options for molecular testing in clinical practice.
CONCLUSIONS
The science of molecular testing has progressed rapidly, but caution must be used when incorporating molecular testing for thyroid nodules into clinical practice. A clear understanding of the goals and limitations of molecular testing must be incorporated into how physicians use and explain molecular testing to patients.
Molecular tests can rule in cancer for indeterminate thyroid nodules with highly specific mutations for cancer, such as BRAF and RET/PTC, and can reduce completion thyroidectomy rates for surgeons recommending total thyroidectomy. The PPV of malignant cytology (Bethesda VI) is 98% 3 ; and, although molecular testing improves specificity analysis and PPV, it falls short of this ideal for other mutations. Molecular testing can rule out thyroid cancer for the indeterminate thyroid nodule in selected cases. Indications favoring "rule-out" testing include a low institutional prevalence of cancer for indeterminate thyroid nodules and patients with no high-risk history, physical features, or ultrasound features. The NPV of benign cytology is 96%. 3 Prospective studies suggest that this ideal has been met with several molecular tests, but careful surveillance is recommended given the lack of long-term outcomes. In addition, many of the molecular platforms described herein have limited testing against a true gold standard; because benign nodules, as determined by molecular tests, rarely undergo definitive histologic evaluation. Similarly, the true specificity of molecular tests also must be evaluated in benign nodules to further characterize the accuracy of molecular testing results. 3 Although there is hope that cytomolecular testing can potentially inform treatment decisions regarding the clinically low-risk PTCs that may be indolent; currently, molecular tests fail to improve the predictive ability beyond the TNM classification system. 51 The development of the American Thyroid Association riskstratification system remains the best way to predict future disease recurrence after initial therapy. 3 However, the future of molecular testing in thyroid pathology holds great promise and may inform not only nodule management but also the role for radioactive iodine therapy and potentially systemic therapy as well. Further understanding of the molecular mutations causing thyroid cancer may allow for new drug development for high-risk disease, help identify and change treatment approaches for patients with specific mutations, and allow more directed risk-stratification and prognosis discussions. Early data have already begun to identify specific molecular markers in thyroid cancer associated with negative outcomes and decreased survival. 63 Further research into the implications of molecular testing on treatment decisions and disease prognosis is warranted.
Whereas each test described has its own strengths and limitations, no data compare the performance characteristics of each commercially available test among a given collection of samples. Ideally, future research would include head-to-head comparisons of molecular tests, long-term prospective data, and cost-effectiveness studies; however, currently, clinicians and patients who use the tests must understand and weigh the advantages and limitations.
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